^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    PTPRC expression

    i
    Other names: PTPRC, Protein Tyrosine Phosphatase Receptor Type C, T200, Receptor-Type Tyrosine-Protein Phosphatase C, CD45 Antigen, GP180, CD45, L-CA, LCA, Protein Tyrosine Phosphatase Receptor Type C Polypeptide, T200 Leukocyte Common Antigen, Leukocyte Common Antigen, T200 Glycoprotein, CD45R, PTPRC, B220, LY5
    Entrez ID:
    5788
    Related biomarkers:
    Expression
    Others
    4d
    An Abnormal Clone with a der(12;22)(q10;q10) as a Rare Abnormality Within the Context of dup(1)(q25q43), Deletion of ABL1 and a t(8;21) in a Pediatric Male Patient with Acute Myeloid Leukemia. (PubMed, J Assoc Genet Technol)
    Although it's in the favorable risk stratification category (NCCN Clinical Practice Guidelines 2023), the presence of complex abnormalities, including 1q+, deletion of 12p, and a der(12;22), suggests genomic instability and poor prognosis. The patient died six months post-transplant.
    Journal
    |
    ABL1 (ABL proto-oncogene 1) • KIT (KIT proto-oncogene, receptor tyrosine kinase) • CD38 (CD38 Molecule) • CD123 (Interleukin 3 Receptor Subunit Alpha) • CD33 (CD33 Molecule) • CD34 (CD34 molecule) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • NCAM1 (Neural cell adhesion molecule 1) • CD14 (CD14 Molecule) • CD9 (CD9 Molecule) • ITGAM (Integrin, alpha M) • CD7 (CD7 Molecule) • IL3RA (Interleukin 3 Receptor Subunit Alpha) • ITGAX (Integrin Subunit Alpha X) • ANPEP (Alanyl Aminopeptidase, Membrane)
    |
    PTPRC expression
    16d
    Immune Checkpoint Blockade Enhances the Abscopal Effect of [177Lu]Lu-DOTA-JR11 PRRT in an SSTR2-Heterogeneous Bilateral Tumor Model. (PubMed, Eur J Nucl Med Mol Imaging)
    PRRT combined with PD-L1 blockade remodels the tumor immune microenvironment, elicits potent systemic antitumor immunity, and enhances the abscopal effect in SSTR2-heterogeneous tumors. This strategy may help address target-expression heterogeneity in radionuclide therapy.
    Preclinical • Journal • Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • SSTR (Somatostatin Receptor) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • IL2 (Interleukin 2) • SSTR2 (Somatostatin Receptor 2) • GZMB (Granzyme B)
    |
    PD-L1 expression • PTPRC expression
    21d
    Recurrent SWI/SNF Deficiency Defines a Subset of Peripheral T-cell Lymphoma With Distinct Clinicopathologic Features. (PubMed, Mod Pathol)
    Death due to disease or therapy-related complications occurred in 4/8 (50%) cases in the SWI/SNF-deficient group and 6/7 (86%) of cases in the SWI/SNF-intact group. Our findings expand the knowledge of the clinicopathologic and molecular features of pediatric PTCL and highlight SWI/SNF-deficient T-cell lymphoma as a biologically distinct type of PTCL that is associated with characteristic clinicopathologic features.
    Journal
    |
    TP53 (Tumor protein P53) • PTEN (Phosphatase and tensin homolog) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • CD8 (cluster of differentiation 8) • TET2 (Tet Methylcytosine Dioxygenase 2) • SMARCB1 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily B, Member 1) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • TBX21 (T-Box Transcription Factor 21) • GATA3 (GATA binding protein 3) • SPN (Sialophorin)
    |
    CDKN2A deletion • PTPRC expression
    2ms
    An Atypical Presentation of a Non-neural Granular Cell Tumor. (PubMed, Cureus)
    The prognosis, genetic alterations, and cellular origins of these tumors remain poorly understood. The findings included in this report will hopefully inform future investigations into the nature of NNGCTs and ultimately lead to improved treatment outcomes.
    Journal
    |
    PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • CD68 (CD68 Molecule)
    |
    PTPRC expression
    3ms
    Blastoid Mantle Cell Lymphoma in the Leukemic Phase: Resolving a Morphological Dilemma Through Flow Cytometry. (PubMed, Cureus)
    Flow cytometric immunophenotyping demonstrated bright CD45 expression with low side scatter and positivity for CD19, CD20, CD38, CD5, CD79b, and FMC7 with negativity for CD34, CD23, CD200, and CD10, suggesting blastoid transformation of MCL rather than de novo ALL. This case highlights the critical role of flow cytometry in distinguishing blastoid MCL from acute leukemia, thereby preventing misdiagnosis and ensuring appropriate therapeutic decision-making.
    Journal • IO biomarker
    |
    TP53 (Tumor protein P53) • CD20 (Membrane Spanning 4-Domains A1) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • RB1 (RB Transcriptional Corepressor 1) • CD38 (CD38 Molecule) • CDK4 (Cyclin-dependent kinase 4) • CD79B (CD79b Molecule) • CD34 (CD34 molecule) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • CD5 (CD5 Molecule) • CD200 (CD200 Molecule) • MME (Membrane Metalloendopeptidase) • CDKN2C (Cyclin Dependent Kinase Inhibitor 2C) • FCER2 (Fc Fragment Of IgE Receptor II)
    |
    TP53 mutation • CD20 positive • CDKN2A deletion • RB1 deletion • PTPRC expression
    3ms
    Increased expression of CD36 and CD163 in clear cell renal cell carcinoma suggests an association between lipid transport and an "M2-like" macrophage phenotype. (PubMed, Front Immunol)
    Lipid metabolic markers CD36 and CD147 are expressed in ccRCC tumors and correlations with immune cell subsets suggest their role in suppressing anti-tumor immunity. These findings suggest the existence of a metabolic-immune axis in ccRCC and provide a rationale for targeting TAM metabolism to enhance immunotherapeutic efficacy.
    Journal • IO biomarker
    |
    CD8 (cluster of differentiation 8) • CD163 (CD163 Molecule) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • CD36 (thrombospondin receptor) • CD68 (CD68 Molecule) • BSG (Basigin (Ok Blood Group))
    |
    PTPRC expression
    3ms
    Anaplastic Lymphoma Kinase (ALK)-Positive Large B-cell Lymphoma in Children: A Case Report and Review of Literature. (PubMed, Cureus)
    The patient was treated with CHOP chemotherapy, with alectinib added from the second cycle...Notably, neuron-specific enolase levels increased in parallel with disease progression. This case highlights diagnostic challenges related to an unusual clinical presentation and pathological overlap with other hematologic diseases.
    Journal • IO biomarker
    |
    ALK (Anaplastic lymphoma kinase) • CD38 (CD38 Molecule) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • IRF4 (Interferon regulatory factor 4)
    |
    ALK positive • ALK mutation • PTPRC expression
    |
    Alecensa (alectinib)
    4ms
    The bone marrow niche and hematopoietic system are distinctly remodeled by CD45-targeted astatine-211 radioimmunotherapy. (PubMed, Blood Adv)
    Collectively, our study indicates that CD45-targeted RIT severely impacts hematopoietic and EC niche recovery compared to non-targeted approaches. Future studies are required to determine the long-term consequences of such RIT-driven effects on BM niche physiology and how BM niche reprogramming by RIT affects cancer cells.
    Journal • IO biomarker
    |
    PTPRC (Protein Tyrosine Phosphatase Receptor Type C)
    |
    PTPRC expression
    4ms
    Evaluating murine double minute 2 status as a stratification tool for risk-adapted management in plasma cell neoplasms. (PubMed, World J Clin Oncol)
    IHC-detected MDM2 overexpression identifies a distinct subset of plasma cell neoplasms characterized by reduced early treatment responsiveness and significantly shorter RFS. These findings support the potential of MDM2 as a prognostic biomarker for early relapse risk in MM. Incorporating MDM2 assessment into diagnostic and prognostic workflows may enable more individualized treatment approaches. Further validation through prospective studies is recommended.
    Preclinical • Journal
    |
    TP53 (Tumor protein P53) • MDM2 (E3 ubiquitin protein ligase) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C)
    |
    PTPRC expression
    5ms
    Russell Body Gastritis: Histochemical and Immunohistochemical Findings in a Series of Three Patients. (PubMed, Int J Surg Pathol)
    Histochemical and immunohistochemical stains are useful ancillary diagnostic tools. The occurrence of this phenomenon in certain patients with compromised immune systems is clinically significant and requires validation.
    Journal • IO biomarker
    |
    CD38 (CD38 Molecule) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • SDC1 (Syndecan 1) • CD79A (CD79a Molecule)
    |
    PTPRC expression
    6ms
    Characterizing circulating rare cells in peripheral blood for detecting and monitoring multiple myeloma and precursor states. (PubMed, NPJ Precis Oncol)
    Shifts in BCMA and CD45 expression suggested immune cell profile alterations with progression and treatment. These findings underscore PB-based liquid biopsy as a promising tool for MM detection and monitoring, revealing circulating PC heterogeneity.
    Journal • IO biomarker
    |
    PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • SDC1 (Syndecan 1)
    |
    PTPRC expression
    6ms
    Age-related immune states and PD-1 blockade: mechanisms and strategies for the elderly. (PubMed, J Immunother Cancer)
    Its supplementation has been shown to improve programmed cell death-1 blockade responsiveness in aged mice. Although clinical studies in humans have yielded inconsistent results regarding the effect of chronological age on ICI efficacy, identifying patients with "age-related" immune microenvironments may enable stratified therapeutic approaches based on insights from preclinical aging models.
    Review • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C)
    |
    PTPRC expression